The US Food and Drug Administration (FDA) has cleared Novaliq’s Investigational New Drug (IND) application for NOV05, enabling the initiation of the EYETAC phase II clinical trial ( NCT07285070) in ...
HOUSTON, Dec. 31, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development ...
FibroBiologics (FBLG) announced the filing of a Phase 1/2 Investigational New Drug application with the U.S. Food and Drug Administration seeking regulatory clearance to initiate clinical trials of ...
IND clearance marks the first ever cellular rejuvenation therapy using partial epigenetic reprogramming to reach human ...
BOSTON, Mass, April 01, 2025 (GLOBE NEWSWIRE) -- Radiance Biopharma, Inc. (“Radiance” or the “Company”), a clinical stage biopharmaceutical company advancing Antibody Drug Conjugates (‘ADCs’), today ...
Imagion Biosystems has submitted an Investigational New drug Application with the US FDA for its MagSense imaging agent for breast ... Read More The post Imagion Biosystems lodges IND application for ...
The application follows guidance provided to IMUNON (IMNN) in Pre-IND meeting with the FDA LAWRENCEVILLE, N.J., March 13, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage ...
The FDA cleared an investigational new drug application to advance NOV05 in a phase 2 clinical trial in noninfectious ...
BOSTON, Mass, March 31, 2025 (GLOBE NEWSWIRE) -- Radiance Biopharma, Inc. (“Radiance” or the “Company”), a clinical stage biopharmaceutical company advancing Antibody Drug Conjugates (‘ADCs’), today ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results